"Evidently, it is a case of oversight and deviation from set processes at an operative and supervisory level at the facility in question," Wockhardt Ltd Founder Chairman and Group CEO Habil Khorakiwala told shareholders at the company's 14th Annual General Meeting earlier this month.
Admittedly, it is an inexcusable lapse but the company has taken swift and definitive action, both corrective and pre-emptive, he added.
"These measures will ensure that the operative people in the organisation do not deviate from following the systems and processes laid down," Khorakiwala said.
In July, the Mumbai-based firm had received a warning letter from US Food and Drug Administration (USFDA) over its facility at Waluj in Maharashtra for not meeting manufacturing norms.
The company had earlier in May announced that the USFDA had issued an import alert on its Waluj facility, which makes injectables and solid dosages. According to the company's estimates, the import alert issued by the USFDA could impact the company's business by $100 million.
UK drug regulator, Medicines and Healthcare products Regulatory Agency (MHRA) had also pulled up the firm for manufacturing shortcomings.
Outlining the initiatives being taken up by the company to firm up the manufacturing process, Khorakiwala said Wockhardt has appointed a new Head of Quality reporting directly to the Managing Director.
"Secondly, we are working with several international consultants and advisors to establish processes enabling a robust system of compliance that will meet all regulatory norms and requirements," he added.
The company is leveraging technology to lay down a system of checks and balances to ensure that operative personnel strictly follow and maintain established processes and protocols mandated, he said.
"We are deploying enterprise-wide software that will streamline the entire quality and compliance system across all our manufacturing facilities," Khorakiwala said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)